Table 1 Patient Demographics

From: Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

 

Encenicline 0.27 mg ( n =107)

Encenicline 0.9 mg ( n =105)

Placebo ( n =105)

Male/female, n

70:37

75:30

70:35

Mean (SD) age, years

39.1 (9.7)

37.3 (10.5)

39.2 (9.9)

 Range, years

21–55

18–55

20–54

 Number (%) >30 years

80 (74.8)

72 (68.6)

79 (75.2)

Mean (SD) BMI, kg/m2

27.0 (4.2)

27.7 (4.3)

28.1 (4.4)

Race, n (%)

 White

72 (67.3)

64 (61.0)

72 (68.6)

 Black or African American

32 (29.9)

37 (35.2)

31 (29.5)

 Asian

3 (2.8)

1 (1.0)

2 (1.9)

 Other

0

3 (2.9)

0

Smoking or tobacco use, n (%)

55 (51.4)

57 (54.3)

66 (62.9)

Onset ≥10 years, n (%)

63 (58.9)

50 (47.6)

63 (60.0)

Current antipsychotic, n (%)

 Risperidone

51 (47.7)

53 (50.5)

52 (49.5)

 Quetiapine

22 (20.6)

16 (15.2)

22 (20.9)

 Olanzapine

17 (15.9)

7 (6.7)

11 (10.5)

 Aripiprazole

10 (9.3)

8 (7.6)

12 (12.4)

 Paliperidone

4 (3.7)

13 (12.4)

4 (3.8)

 Other

3 (2.8)

8 (7.6)

4 (3.8)

Back to article page